The latest update is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group Inc. has announced its audited financial results for the year ending December 31, 2024. The release of these results, which comply with the Hong Kong Stock Exchange’s listing requirements, provides stakeholders with insights into the company’s financial performance and strategic positioning. The full annual report will be available in April 2025, offering further details on the company’s operations and governance.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a joint stock company incorporated in China, operating within the pharmaceutical industry. The company focuses on the development, production, and sale of pharmaceutical products, catering to various healthcare needs.
YTD Price Performance: -1.45%
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.99B
For a thorough assessment of 1513 stock, go to TipRanks’ Stock Analysis page.